Research & Advanced Technologies


The metabolism of T3 and T4 combination therapy into active and inactive intermediates involves the action of 3 types of deiodinases. Recent studies of common genetic variations in deiodinase and thyroid hormone transport proteins offer fresh insights in understanding the variable response to thyroid hormone therapy and future research may clarify whether subsets of patients will benefit from challenges and improvements to combination therapy. Despite significant challenges, opportunities abound for improving the Thyroid Treatment Augments Psychiatric Therapy and also Improvements of Reproductive, Neuro-endocrinology or Neuroendocrine Function in Hypothalamic.

 

  • type 1 diabetes risk.
  • Understanding the biology of body-weight regulation in children.
  • Molecule to improve continuous glucose monitoring.
  • Legacy effect of diabetes
  • Insulin-producing beta-cells

Related Conference of Research & Advanced Technologies

February 24-25, 2025

34th European Diabetes Congress

London, UK
March 10-11, 2025

4th Global Summit on Physiology and Metabolism of Thyroid

Singapore City, Singapore
March 17-18, 2025

5th European Endocrinology and Diabetes Congress

Paris, France
April 10-11, 2025

5th World Congress on Endocrine and Diabetes

Dubai, UAE
April 10-11, 2025

4th International Summit on Hormonal Disorders

Dubai, UAE
May 19-20, 2025

6th World Summit on Diabetes

Rome, Italy
June 04-05, 2025

4th World Congress on Diabetes and Pediatric Endocrinology

Edinburgh, Scotland
July 29-30, 2025

15th World Congress on Endocrinology and Diabetes

Aix-en-Provence, France
September 08-09, 2025

3rd World congress and Expo on Diabetes

Frankfurt, Germany
November 20-21, 2025

21st World Congress on Endocrinology & Diabetes

Aix-en-Provence, France

Research & Advanced Technologies Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in